New EndoTool IV Data Presented at AACE Show
Glooko, Inc. announced data at the AACE Annual Meeting showing that EndoTool IV led to a virtual elimination of severe hypoglycemia across 19 hospitals, based on a three-year retrospective analysis from January 2023 to December 2025.
PALO ALTO, Calif. & LAS VEGAS–(BUSINESS WIRE)–Glooko, Inc., a globally integrated digital healthcare company focused on helping healthcare systems solve the growing challenges of glycemic safety and diabetes management across care settings, today announced data presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting. The evidence, reflecting outcomes from a three-year retrospective analysis spanning from January 2023 through December 2025, demonstrated that EndoT